🔗 Visit the ClinicalTrials.gov page for NCT00636558
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. | Mol Ther | 2013 | 0.84 |
| 2 | Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. | Front Oncol | 2014 | 0.82 |
| 3 | Oncolytic virotherapy for multiple myeloma: past, present, and future. | Bone Marrow Res | 2011 | 0.79 |
| 4 | Oncolytic virotherapy for urological cancers. | Nat Rev Urol | 2016 | 0.76 |
| 5 | Promising oncolytic agents for metastatic breast cancer treatment. | Oncolytic Virother | 2015 | 0.76 |